AMYLISYN

This platform combines two complementary biological signals:

* GLP-1 Peptide: Supports the body’s recognition of having received sufficient energy intake.
* Long-Acting Amylin Analogue: Supports the maintenance of postprandial satiety and prolonged fullness.

Together, these two signals form the concept of: Synergistic Satiety – Sustained physiological satiety achieved through two complementary biological mechanisms.

SCIENTIFIC FOUNDATION

GLP-1 and Amylin are two important physiological hormones involved in the regulation of eating behavior and energy homeostasis.

#GLP-1 – The “I’ve Had Enough” Signal
GLP-1 is a naturally occurring incretin hormone released from the intestine following food intake. Activation of GLP-1 receptor signaling has been associated with:

• Reduced hunger sensation.
• Increased satiety during meals.
• Delayed gastric emptying.
• Support of glucose-dependent insulin response.
• More efficient energy utilization.

#Amylin – The “I’m Still Full” Signal
Amylin is secreted alongside insulin from pancreatic beta cells. Activation of Amylin receptor signaling has been associated with:

• Prolonged satiety between meals.
• Reduced tendency for frequent eating.
• Support of portion control.
• Regulation of postprandial glucagon response.
• Partial modulation of emotional eating behaviors.

SYNERGISTIC EFFECT

GLP-1 and Amylin act through distinct but complementary central and peripheral pathways.
* GLP-1 helps the body recognize: “I have eaten enough.”
* Amylin helps maintain: “I am still full.”

Together, these mechanisms influence two critical phases of eating behavior:
#Phase 1 – Satiation
Recognition of fullness and meal termination.

#Phase 2 – Satiety
Maintenance of fullness between meals and reduction of unnecessary food intake.

This concept forms the scientific basis of: Synergistic Satiety

SCIENTIFIC AND CLINICAL EVIDENCE

Over recent years, multiple studies have evaluated the potential of combining GLP-1 receptor agonists and Amylin analogues in energy regulation.

#The REDEFINE Clinical Development Program
REDEFINE is a large-scale Phase III clinical research program evaluating a specific combination model involving a GLP-1 receptor agonist and a long-acting Amylin analogue.

#REDEFINE-1

• 3,417 participants.
• 68-week follow-up.
• Population: Overweight or obese individuals without Type 2 Diabetes.

Key findings:

• Average weight reduction of 20.4%.
  Compared with 14.9% in the GLP-1 monotherapy group.
• Compared with 11.5% in the Amylin analogue monotherapy group.
• Approximately 40.4% of participants achieved ≥25% body weight reduction.

#REDEFINE-2

• 1,206 participants.
• 68-week follow-up.
• Population: Overweight or obese individuals with Type 2 Diabetes.

Key findings:

• Average weight reduction of 13.7%.
  Significant improvements in glycemic control parameters were also observed.

These findings contribute to the growing hypothesis that combining GLP-1 and Amylin may produce synergistic effects on energy regulation pathways.

SCIENTIFIC POSITIONING OF AMYLISYN

AMYLISYN is not built upon the philosophy of “the less you eat, the better.” Instead, this platform aims to:

• Support recognition of physiological satiety.
• Support maintenance of fullness between meals.
• Promote more natural regulation of eating behavior.
• Expand scientific understanding of energy regulation mechanisms.
• Complement evidence-based nutrition and healthy lifestyle strategies.

PRACTICAL RESEARCH CONSIDERATIONS

# Proposed Research Dosing Strategy
AMYLISYN 10 mg

Containing:
GLP-1 Peptide: 5 mg
Amylin Analogue: 5 mg

#Suggested Dose Escalation Model

• Week 1: Initiate at the lowest dose of 0.25 mg/week.
• Increase by 0.25 mg weekly if desired research outcomes have not yet been observed.
• Maximum proposed dose: 2.4 mg/week.
• Individuals with prior exposure to GLUVERA or SATILYN monotherapy without satisfactory outcomes may consider initiating at 0.5 mg/week.

#Guiding Principles

• Start low.
• Escalate gradually.
• Individualize according to tolerability.
• Reaching the maximum dose is not mandatory.

RESEARCH POPULATION CONSIDERATIONS

AMYLISYN may represent an area of interest in research involving individuals who exhibit:

• Difficulty controlling portion sizes.
• Frequent eating throughout the day.
• Emotional eating behavior.
• Short-lived satiety with rapid return of hunger.
• Tendency toward weight regain after successful weight loss.
• Need for improved regulation of eating behavior and energy balance.
• Suboptimal outcomes with GLP-1 or Amylin analogue monotherapy.

SAFETY AND CONTRAINDICATIONS

#Commonly Reported Reactions
* Nausea.
* Constipation.
* Diarrhea.
* Vomiting.
* Abdominal fullness or bloating.
* Transient fatigue.
* Mild injection-site redness or irritation.

Most of these reactions occur during the dose-escalation phase and tend to diminish over time.

#Use With Caution in Individuals With:
* History of pancreatitis.
* Significant gastrointestinal disorders.
* Severe delayed gastric emptying.
* Risk of malnutrition or unintended weight loss.

#Research Participation Is Generally Not Recommended In Individuals With:
* Personal or family history of Medullary Thyroid Carcinoma (MTC).
* Multiple Endocrine Neoplasia Type 2 (MEN2).
* Known hypersensitivity to related peptides.
* Pregnancy or breastfeeding.

THE PHILOSOPHY OF JN BEAUTY SOLUTIONS®

We believe that genuine science is not about forcing the body to change, but about gaining a deeper understanding of the physiological mechanisms that already exist.

AMYLISYN was built upon this philosophy: NOT AGAINST THE BODY – NOT FORCING THE BODY but rather seeking to understand and support the natural balance between:
Hunger ↔ Satiety ↔ Metabolism ↔ Long-Term Health

CONCLUSION

AMYLISYN represents a new direction in metabolic research, where GLP-1 and Amylin signaling are viewed as complementary components of the same energy-regulating system.

Through the concept of Synergistic Satiety, this platform contributes to expanding scientific understanding of eating behavior, physiological satiety, and the mechanisms involved in energy homeostasis.

AMYLISYN – THE SCIENCE OF SUSTAINABLE PHYSIOLOGICAL SATIETY
Two biological signals. One natural balance. A new vision for metabolic science.
Advanced GLP-1 & Amylin Synergy Platform. RESEARCH USE ONLY

For additional information, please contact:
JN Beauty Solutions®
Beauty From Science